Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.
HER2 mutation
Lung adenocarcinoma
Management
Prognosis
Target therapy
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
13
04
2019
pubmed:
4
6
2019
medline:
11
6
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC). The objective was to investigate the clinical characteristics and management of HER2-mutated NSCLCs in a real-life setting. This multicenter study described NSCLCs harboring HER2 mutations diagnosed between January 2012 and December 2014, according their clinical characteristics, management, and outcomes: response rate (RR), progression-free survival (PFS), and overall survival (OS). Thirty patients were included: 66.7% women; median age 65.2 ± 12 years; never or former smokers 73.3%. Of the stage IV patients (n = 23), 86% received first-line platin doublet chemotherapy: RR 61.5% and PFS 6.7 (95% CI 5.9-9.5) months; 52.1% received a second-line therapy: RR 18.2% and PFS 4.9 (95% CI 2.5-11.9) months. Median OS of stage IV was 10.7 months and 2-year OS was 27.2% (95% CI 11.7-63.2). All patients with stage I-III NSCLCs were alive at 2 years. The rarity of HER2-mutated NSCLCs requires specific studies.
Sections du résumé
BACKGROUND
Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC). The objective was to investigate the clinical characteristics and management of HER2-mutated NSCLCs in a real-life setting.
METHODS
This multicenter study described NSCLCs harboring HER2 mutations diagnosed between January 2012 and December 2014, according their clinical characteristics, management, and outcomes: response rate (RR), progression-free survival (PFS), and overall survival (OS).
RESULTS
Thirty patients were included: 66.7% women; median age 65.2 ± 12 years; never or former smokers 73.3%. Of the stage IV patients (n = 23), 86% received first-line platin doublet chemotherapy: RR 61.5% and PFS 6.7 (95% CI 5.9-9.5) months; 52.1% received a second-line therapy: RR 18.2% and PFS 4.9 (95% CI 2.5-11.9) months. Median OS of stage IV was 10.7 months and 2-year OS was 27.2% (95% CI 11.7-63.2). All patients with stage I-III NSCLCs were alive at 2 years.
CONCLUSION
The rarity of HER2-mutated NSCLCs requires specific studies.
Identifiants
pubmed: 31154630
doi: 10.1007/s12325-019-01001-9
pii: 10.1007/s12325-019-01001-9
pmc: PMC6822870
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Epidermal Growth Factor
62229-50-9
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Banques de données
figshare
['10.6084/m9.figshare.8138837']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2161-2166Subventions
Organisme : GFPC
ID : 17/2
Pays : International
Références
Clin Cancer Res. 2012 Sep 15;18(18):4910-8
pubmed: 22761469
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
pubmed: 23610105
J Thorac Oncol. 2016 Mar;11(3):414-9
pubmed: 26723242
BMC Cancer. 2016 Oct 28;16(1):828
pubmed: 27793199
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Ann Oncol. 2004 Jan;15(1):19-27
pubmed: 14679114
Ann Oncol. 2015 Jul;26(7):1421-7
pubmed: 25899785
J Thorac Oncol. 2017 Mar;12(3):446-457
pubmed: 27903463
Lung Cancer. 2012 Apr;76(1):123-7
pubmed: 22325357
Clin Lung Cancer. 2018 Sep;19(5):e775-e781
pubmed: 30149884
Lung Cancer. 2016 Sep;99:53-6
pubmed: 27565914
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Ann Oncol. 2016 Feb;27(2):281-6
pubmed: 26598547